Table 1.
Baseline characteristics of patients
| Baseline characteristics of the study population population (n = 105) | N (%) |
|---|---|
| Age, years | |
| Mean | 47 |
| SUVmean | 3.92 ± 2.05 |
| SUVmax | 6.25 ± 3.73 |
| SUVmin | 1.63 ± 0.69 |
| ER status | |
| Positive | 83 (79.05%) |
| Negative | 22 (20.95%) |
| PR status | |
| Positive | 88 (83.8%) |
| Negative | 17 (16.2%) |
| Ki67 | |
| Positive | 83 (79.05%) |
| Negative | 22 (20.95%) |
| Molecular subtype | |
| HR-positive/HER2-negative | 66 (62.29%) |
| HER2-positive | 31 (29.52%) |
| TNBC | 8 (8.19%) |
| Menopausal status | |
| Premenopausal | 37 (35.24%) |
| Postmenopausal | 68 (64.76%) |
| Prechemotherapy T stage | |
| T1 | 12 (11.43%) |
| T2 | 56 (53.33%) |
| T3 | 19 (18.1%) |
| T4 | 18 (17.14%) |
| Prechemotherapy N stage | |
| N0 | 21 (20%) |
| N1 | 36 (34.29%) |
| N2 | 35 (33.33%) |
| N3 | 13 (12.38%) |
| Prechemotherapy stage | |
| II | 47 (44.76%) |
| III | 58 (55.24%) |
| Event | |
| Yes | 22 (20.95%) |
| No | 83 (79.05%) |
| RCB | |
| I | 15 (14.29%) |
| II | 48 (45.71%) |
| III | 42 (40%) |
ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor 2; HR hormone receptor positive; TNBC triple-negative breast cancer; RCB residual cancer burden